[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"car-t\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:car-t":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,43,72,98,131,152],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100478773","a-study-of-ultra-fraction-radiotherapy-bridging-cart-in-rr-dlbcl-100478773",false,"NCT05514327","A Study of Ultra-fraction Radiotherapy Bridging CART in R\u002FR DLBCL","the Safety and Efficacy of Ultra-fraction Radiotherapy Bridging CART Cell Therapy in Relapsed\u002FRefractory Diffuse Large b Cell Lymphoma","Inclusion Criteria:\n\n1. Over than 18 years old\n2. Histologically confirmed DLBCL(by central pathology review before enrolment)\n3. Relapsed or refractory disease after ≥2 lines of chemotherapy including rituximab and anthracycline and either having failed autologous Hematopoietic stem cell transplantation (ASCT), or being ineligible for or not consenting to ASCT\n4. Measurable disease at time of enrollment (the maximum diameter of cross section ≥1.5cm)\n5. Life expectancy ≥12 weeks\n6. Able to receive radiotherapy evaluated by specialist\n\nExclusion Criteria:\n\n1. Prior radiation therapy within 1 year of infusion\n2. Pregnant or nursing (lactating) women\n3. Uncontrolled acute life threatening bacterial, viral or fungal infection (e.g. blood culture positive ≤ 72 hours prior to infusion)\n4. Previous solid tumor within 3 years, previous or concurrent hematological malignancy\n5. Severe organ dysfunction: left ventricle ejection fraction (LVEF) \\\u003C40%; DLCO \\\u003C40%; estimated glomerular filtration rate (eGFR)\\\u003C30mL\u002Fmin\u002F1.73 m2; total bilirubin \\>3 ULN\n6. HIV positive patients, active replication of or prior infection with hepatitis B or active hepatitis C( HCV RNA positive );\n7. Other conditions that the investigator may exclude due to risks or other possibilities","ALL","18 Years",{"count":19,"type":20},20,"ESTIMATED","INTERVENTIONAL",[23],"NA","This is a single-arm single center study to prospectively evaluate the safety and efficacy of ultra-fraction radiotherapy bridging CAR-T therapy in relapsed\u002Frefractory diffuse large b cell lymphoma",[26,27,28,29],"Diffuse Large B Cell Lymphoma","CAR-T","Radiotherapy","Bridging Therapy","RECRUITING","2026-03-23",{"date":33,"type":34},"2026-03-24","ACTUAL",{"date":36,"type":34},"2022-09-01",{"date":38,"type":20},"2028-12-01",{"name":40,"class":41},"Peking Union Medical College Hospital","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":52,"conditions":53,"keywords":60,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":42},"100441118","long-term-follow-up-of-subjects-treated-with-car-t-cells-100441118","NCT05024175","Long-term Follow-up of Subjects Treated With CAR T Cells","Inclusion Criteria:\n\nSubjects will be asked to participate leading up to the last DF\u002FHCC corresponding main study visit.\n\nSubjects meeting the following criteria are eligible for study participation:\n\n* Provision of voluntary written informed consent by subject\n* CAR T cells were administered in DF\u002FHCC IRB corresponding main study\n\nExclusion Criteria:\n\nSubjects meeting the following criterion are to be excluded from study participation:\n\n\\- Subject unable to comply with study requirements",{"count":50,"type":20},45,"OBSERVATIONAL","This is a single site, non-randomized, open-label, long-term safety and efficacy follow-up study for Phase 1 studies that evaluate the safety and efficacy of CAR T cells: NCT05660369 (DF\u002FHCC# 22-175) and NCT06026319 (DF\u002FHCC# 23-474).",[54,27,55,56,57,58,59],"Long Term Adverse Effects","Duty to Follow Up","Adult","Progression-Free Survival","Disease-Free Survival","Overall Survival",[61,62],"Long-Term Follow-up to CAR-T Cells","Follow-up Studies","2026-03-13",{"date":65,"type":34},"2026-03-16",{"date":67,"type":34},"2023-08-07",{"date":69,"type":20},"2039-08-01",{"name":71,"class":41},"Marcela V. Maus, M.D.,Ph.D.",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":16,"minAge":79,"maxAge":17,"enrollmentInfo":80,"targetDuration":4,"studyType":21,"phases":82,"briefSummary":84,"conditions":85,"keywords":87,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":94,"leadSponsor":96,"locationsCount":4},"100618956","early-phase-1-clinical-study-of-cll-1-car-t-in-the-treatment-of-children-with-rr-aml-100618956","NCT07338357","Clinical Study of CLL-1 CAR-T in the Treatment of Children With R\u002FR AML","A Single-Center Clinical Study Evaluating the Safety and Preliminary Efficacy of CLL-1 CAR-T in the Treatment of Children With Relapsed\u002FRefractory Acute Myeloid Leukemia","Inclusion Criteria:\n\n1. Voluntarily sign the ICF and are expected to complete the study's follow-up examinations and procedures.\n2. Aged 3 to 18 years (inclusive), and body weight ≥10 kg.\n3. Diagnosis of AML according to the 2016 WHO classification, meeting the diagnostic criteria for relapse and refractoriness as per the \"Chinese Guidelines for Diagnosis and Treatment of Relapsed\u002FRefractory Acute Myeloid Leukemia (2017 Edition)\", and currently having no clinically relevant treatment options or suitable registered clinical trials available.\n4. Confirmation of CLL-1 expression ≥50% on AML blasts by flow cytometry.\n5. Recovery from toxicities of prior therapies.\n6. Karnofsky score (for age ≥16 years) ≥70 or Lansky score (for age \\\u003C16 years) ≥50 at screening, and an expected survival \\>3 months.\n7. Suitable function of the liver, kidneys, hematological system, lungs and heart is required.\n8. Females subjects of childbearing potential must have a negative blood pregnancy test at screening and agree to use effective contraception during the study and within 1 year after the last dose of study drug.\n9. Male subjects with reproductive potential must agree to use barrier contraception or practice complete abstinence until 1 year after the last study treatment.\n10. Eligible blood cell specimen can be provided.\n\nExclusion Criteria:\n\n1. Diagnosis of APL.\n2. History of other malignancies within 3 years prior to screening, except for adequately treated carcinoma in situ of the cervix, papillary thyroid carcinoma, basal cell or squamous cell skin cancer, localized prostate cancer treated with radical surgery, and ductal carcinoma in situ treated with radical surgery.\n3. Evidence of CNS involvement or cranial nerve pathology.\n4. Subjects with active infections such as hepatitis B, hepatitis C, etc., are to be excluded.\n5. Subjects with a history of severe allergies or known allergy to any drug component included in this study are to be excluded.\n6. Subjects with severe cardiac diseases, refractory hypertension, active neurological autoimmune or inflammatory diseases, clinically significant active cerebrovascular disease, oncologic emergencies requiring urgent intervention, acute or chronic GVHD, or any uncontrolled infections requiring antibiotic therapy, etc., are unsuitable for enrollment.\n7. Previous organ transplant or planned organ transplant (except for hematopoietic stem cell transplantation).\n8. Received allo-HSCT within 6 weeks prior to screening.\n9. Subjects who have recently undergone major surgery or plan to undergo major surgery, excluding diagnostic procedures and biopsies.\n10. Subjects with severe mental disorders, alcoholism, or drug abuse.\n11. Subjects who, in the judgment of the investigator, have other conditions that make them unsuitable for enrollment.","3 Years",{"count":81,"type":20},10,[83],"EARLY_PHASE1","A study to evaluate the safety and preliminary efficacy of CLL-1-targeted CAR-T cell therapy in children aged 3 to 18 years with relapsed or refractory acute myeloid leukemia (r\u002Fr AML).",[86,27],"AML (Acute Myeloid Leukemia)",[88,27],"R\u002FR AML","NOT_YET_RECRUITING","2026-01-05",{"date":92,"type":34},"2026-01-13",{"date":90,"type":20},{"date":95,"type":20},"2028-10-31",{"name":97,"class":41},"First Affiliated Hospital of Guangxi Medical University",{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":105,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":107,"conditions":108,"keywords":115,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":130},"100145560","cibmtr-research-database-100145560","NCT01166009","CIBMTR Research Database","Protocol For A Research Database For Hematopoietic Stem Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries","Eligibility to Participate in the Research Database\n\nRecipient Eligibility Criteria:\n\n* Any recipient of an unrelated or related donor or autologous HSC transplant in a CIBMTR center is eligible to participate in the Research Database. This includes adults with and without decision making capacity, and children.\n\nIndividual with Marrow Toxic Injury Eligibility Criteria:\n\n* Any individual who is treated for a marrow toxic injury at a center participating in the NMDP's Radiation Injury Transplant Network (RITN) is eligible to participate in the Research Database. This includes adults with and without decision making capacity, and children. Eligible individuals may have received supportive care only, growth factor support, HSC transplant or other appropriate medical treatment for marrow toxic injury. Treatments applied are at the discretion of the care facility, and are not determined by the NMDP or CIBMTR.\n\nUnrelated Donor Eligibility Criteria:\n\n* All donors registered on the NMDP Registry who have been requested to donate a product for a recipient are eligible to participate in the Research Database.\n* All maternal cord blood donors are enrolled in the NMDP Cord Blood Bank Investigational New Drug (IND) protocol, and sign an informed consent document specific to that protocol. Data collected as part of the Cord Blood Bank protocol are included in the Research Database.",{"count":106,"type":20},99999999,"The primary purpose of the Research Database is to have a comprehensive source of observational data that can be used to study HSC transplantation and cellular therapies.\n\nA secondary purpose of the Research Database is to have a comprehensive source of data to study marrow toxic injuries.\n\nObjectives:\n\nTo learn more about what makes stem cell transplants and cellular therapies work well such as:\n\n* Determine how well recipients recover from their transplants or cellular therapy;\n* Determine how recovery after a transplant or cellular therapy can be improved;\n* Determine how a donor's or recipient's genetics impact recipient recovery after a transplant or cellular therapy;\n* Determine how access to transplant or cellular therapy for different groups of patients can be improved;\n* Determine how well donors recover from the collection procedures.",[109,110,111,112,27,113,114],"Autologous Stem Cell Transplantation","Allogeneic Stem Cell Transplantation","Solid Tumors","Blood Cancers","Gene Therapy","Non-malignant Disease",[116,117,118,119,113,27],"Data Collection","CIBMTR","NMDP","Stem Cell Transplantation","2025-08-07",{"date":122,"type":34},"2025-08-12",{"date":124,"type":4},"2002-07",{"date":126,"type":20},"2050-07",{"name":128,"class":129},"Center for International Blood and Marrow Transplant Research","NETWORK",2,{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":135,"acronym":4,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":137,"targetDuration":4,"studyType":21,"phases":138,"briefSummary":141,"conditions":142,"keywords":4,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":148,"leadSponsor":150,"locationsCount":42},"100586571","phase-1-exploratory-clinical-study-on-the-safety-and-efficacy-of-car-t-cell-therapy-in-the-treatment-of-relapsedrefractory-myeloid-malignancies-100586571","NCT06917105","Exploratory Clinical Study on the Safety and Efficacy of CAR-T Cell Therapy in the Treatment of Relapsed\u002FRefractory Myeloid Malignancies","Inclusion Criteria:\n\n* Informed Consent: Willing and able to provide written informed consent, with commitment to comply with scheduled visits, study treatment, laboratory tests, and other trial procedures.\n\nAge: ≥18 years, regardless of gender.\n\nDiagnosis: Pathologically confirmed myeloid malignancy (including but not limited to AML or MDS) meeting relapsed\u002Frefractory criteria:\n\nRelapsed Disease: Reappearance of leukemic cells in peripheral blood, bone marrow blasts \\>5%, or extramedullary relapse after achieving CR\u002FCRi with ≥2 lines of salvage therapy.\n\nRefractory Disease: Failure to achieve CR\u002FCRi after ≥2 cycles of standard intensive chemotherapy.\n\nAntigen Expression: Tumor cell positivity for CD33, CD123, and\u002For CLL-1 confirmed by immunohistochemistry (IHC) or flow cytometry.\n\nLife Expectancy: ≥3 months from the date of informed consent signing. Hematologic Criteria: Hemoglobin ≥70 g\u002FL (transfusion permitted).\n\nOrgan Function:\n\nRenal: Serum creatinine ≤1.5×ULN. Cardiac: Left ventricular ejection fraction (LVEF) ≥50%. Pulmonary: Oxygen saturation \\>90% on room air. Hepatic: Total bilirubin ≤1.5×ULN; ALT\u002FAST ≤2.5×ULN. Performance Status: Eastern Cooperative Oncology Group (ECOG) performance status score 0-2.\n\nExclusion Criteria:\n\n* Cardiac Dysfunction: Severe cardiac insufficiency with left ventricular ejection fraction (LVEF) \\\u003C50%.\n\nPulmonary Disease: History of severe pulmonary dysfunction (e.g., chronic respiratory failure, interstitial lung disease, or pulmonary hypertension requiring oxygen therapy).\n\nConcurrent Malignancy: Active\u002Fprogressive malignancy other than myeloid neoplasms (exceptions: adequately treated non-melanoma skin cancer or carcinoma in situ).\n\nUncontrolled Infection: Active severe infection requiring systemic antimicrobial therapy (antibacterial, antiviral, or antifungal) without clinical resolution.\n\nImmune Disorders:\n\nSevere autoimmune disease requiring immunosuppressive therapy within 6 months. Primary immunodeficiency disorders (e.g., common variable immunodeficiency, severe combined immunodeficiency).\n\nViral Infections:\n\nActive hepatitis B (HBV-DNA ≥2000 IU\u002FmL) or hepatitis C (HCV-RNA positive). HIV infection, AIDS, or untreated syphilis (confirmed by serological testing). Hypersensitivity: History of severe allergic reaction (Grade ≥3) to biological products, including antibiotics.\n\nTransplant Complications: Allogeneic hematopoietic stem cell transplant recipients with:\n\nAcute graft-versus-host disease (GvHD) ≥ Grade II within 3 months. Ongoing immunosuppressive therapy for GvHD within 4 weeks.\n\nGeneral Exclusion:\n\nAny physical, psychiatric, or laboratory abnormality that may:\n\nSignificantly increase study risk (e.g., uncontrolled diabetes, NYHA Class III\u002FIV heart failure).\n\nCompromise protocol compliance or data interpretation. Investigator-determined unsuitability for trial participation.",{"count":50,"type":20},[139,140],"PHASE1","PHASE2","This is an open-label, single-arm, exploratory clinical trial utilizing a \"3+3\" dose escalation followed by dose expansion to evaluate the safety, maximum tolerated dose (MTD), pharmacokinetics (PK), and preliminary efficacy of CD33\u002FCD123\u002FCLL-1 CAR-T cell therapy in patients with relapsed\u002Frefractory myeloid malignancies.\n\nPart A: Dose Escalation Phase. Follows a \"3+3\" dose escalation design with four predefined dose cohorts: 0.2×10⁶, 0.5×10⁶, 1×10⁶, and 2×10⁶ CAR-positive cells\u002Fkg.Anticipated enrollment: 12-24 subjects.Primary objectives: Assess safety, tolerability, and determine MTD.Dose-limiting toxicity (DLT) observation period: 28 days post-infusion.\n\nPart B: Dose Expansion Phase.Enrolls 21 additional subjects to receive CAR-T cell infusion at the recommended Phase 2 dose (RP2D) established in Part A.Primary objective: Further evaluate therapeutic efficacy.\n\nOverall Study Objectives:Safety profile of CD33\u002FCD123\u002FCLL-1 CAR-T therapy.Efficacy endpoints (e.g., response rates, survival outcomes).Pharmacokinetic characterization of CAR-T cells (expansion\u002Fpersistence).",[143,27],"Myeloid Malignancies","2025-04-01",{"date":146,"type":34},"2025-04-08",{"date":144,"type":20},{"date":149,"type":20},"2029-04-30",{"name":151,"class":41},"Tongji Hospital",{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":4,"eligibilityCriteria":158,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":159,"enrollmentInfo":160,"targetDuration":4,"studyType":21,"phases":162,"briefSummary":163,"conditions":164,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":42},"100565426","early-phase-1-ex02-car-t-cells-for-relapsed-and-refractory-acute-myeloid-leukemia-100565426","NCT06642025","EX02 CAR-T Cells for Relapsed and Refractory Acute Myeloid Leukemia","An Open-label, Single-arm Clinical Study of EX02 CAR-T Therapy for Relapsed and Refractory Acute Myeloid Leukemia","Inclusion Criteria:\n\n1. According to the Chinese Adult Acute Myeloid Leukemia (AML) Diagnosis and Treatment Guidelines (2023 edition\u002Fprevious edition), patients diagnosed with acute myeloid leukemia (AML) and meeting the diagnostic criteria for refractory AML are eligible, including: initial treatment cases with no response after two courses of standard therapy; relapse within 12 months after achieving complete remission (CR) and failure of consolidation therapy; relapse after 12 months with no response to conventional chemotherapy; two or more relapses; and presence of extramedullary leukemia.\n2. Peripheral blood, bone marrow, or extramedullary lesion specimens showing leukemia cells with positive surface expression of EX02;\n3. ECOG performance status score of 0-2;\n4. Age ≥18 and ≤70 years, any gender;\n5. Blood cell examination meeting the following conditions: hemoglobin \\> 60g\u002FL, normal T lymphocyte count (CD3+) \\> 0.5×10\\^9\u002FL, platelet count \\> 30×10\\^9\u002FL;\n6. Negative pregnancy test for women of childbearing potential before the start of the trial, and agreement to use effective contraception measures during the trial until the final follow-up; male participants of reproductive potential agreeing to use effective contraception measures during the trial until the final follow-up;\n7. Voluntary participation in this clinical study: after fully understanding the study content, voluntary signing of the informed consent form, and commitment to complete all trial procedures and activities.\n\nExclusion Criteria:\n\n1. Active hepatitis A, B, C, HIV infection, or other severe active infections that are not yet controlled;\n2. History of acquired immune deficiency syndrome (AIDS) or long-term use of immunosuppressants due to other diseases (including steroids, equivalent to prednisone \\>15mg\u002Fday);\n3. Conditions of the heart function: a. New York Heart Association (NYHA) class III or IV heart failure; b. Myocardial infarction or coronary artery bypass surgery within the six months prior to enrollment; c. Clinically significant ventricular arrhythmia or unexplained syncope; d. History of severe non-ischemic cardiomyopathy; e. History of cardiac dysfunction (left ventricular ejection fraction \\\u003C45%) within 8 weeks before enrollment;\n4. Pregnant or lactating women; participants (both male and female) unwilling to use contraception;\n5. Severe liver or kidney dysfunction: aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels exceeding 3 times the upper limit of normal, bilirubin exceeding 3 times the upper limit of normal; serum creatinine ≥ 178 μmol\u002FL (decompensated phase);\n6. History of severe allergic reactions to any drugs planned for use in this study;\n7. Recipients of hematopoietic stem cell transplantation must have discontinued immunosuppressants for at least 6 weeks before enrollment and have no signs of graft-versus-host disease;\n8. Other conditions deemed unsuitable for participation in this trial by the investigator.","70 Years",{"count":161,"type":20},9,[83],"This is a early Phase 1 open-label, single-arm clinical study of EX02 CAR-T therapy for relapsed and refractory acute myeloid leukemia.\n\nEach participant will undergo leukapheresis after enrolment, receive treatment of the conditioning chemotherapy of cyclophosphamide and fludarabine, and an an intravenous infusion of CAR-T cells.\n\nEach participant will proceed through the following study procedures:\n\n* Screening\n* Enrollment\u002FLeukapheresis\n* Conditioning chemotherapy\n* CAR T treatment\n* Post-treatment assessment\n* Long-term follow-up",[165,27],"Acute Myeloid Leukemia (AML)","2024-10-13",{"date":168,"type":34},"2024-10-15",{"date":170,"type":34},"2024-09-01",{"date":172,"type":20},"2029-09-01",{"name":174,"class":41},"Zhimin Zhai"]